目的　探讨地尔硫 卓艹 对窦性心动过缓并阵发性心房颤动疗效及安全性。方法　经临床诊断为窦性心动过缓并阵发性心房颤动的病人 2 8例。口服地尔硫 卓艹 ,观察 12周 ,经动态心电图复查。判定标准 :转复窦律或房颤减少 90 %以上 ,为有效。结果　 2 8例病人中 16例有效 ,无药物不良反应 ,心率无明显改变。结论　口服地尔硫 卓艹治疗窦性心动过缓并阵发性心房颤动安全有效。 Objective To investigate the efficacy and safety of diltiazem on sinus bradycardia and paroxysmal atrial fibrillation. Methods Clinical diagnosis of sinus bradycardia and paroxysmal atrial fibrillation in 28 cases. Oral diltiazem abamectin, observed for 12 weeks, the dynamic electrocardiogram review. Criteria: reverse sinus rhythm or atrial fibrillation more than 90%, as effective. Results Of 28 patients, 16 cases were effective, no adverse drug reactions, no significant changes in heart rate. Conclusions Oral diltiazem is safe and effective in treating sinus bradycardia and paroxysmal atrial fibrillation.